ArticleNPJ vaccines2024
A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis.
Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Review
- Pangenome-GuidedPharmaceuticals (Basel, Switzerland) · 2026Article
- Inhalable epitope vaccine 1022-SpaA V3 establishes nasal mucosal fortress against zoonotic Streptococcus suis.BMC veterinary research · 2026Article
- Design and immunoinformatics characterization of a novel multi-epitope vaccine rPRRSV-35N targeting NADC30-like and NADC34-like porcine reproductive and respiratory syndrome virus variants.BMC veterinary research · 2026Article
- Identification of Conserved Cross-Reactive B-Cell Epitopes in CPV1 and CPV2 L1 Proteins with Vaccine Potential.Vaccines · 2026Article
- Virulence and antibiotic resistance characteristics of Pasteurella multocida from sheep: integrated genomic and phenotype analysis.World journal of microbiology & biotechnology · 2026Article
- Streptococcus suis in Asia: epidemiology, transmission and zoonotic risk at the animal-human interface.Veterinary research communications · 2026Review
- SSU_RS09155, a virulence-associated gene encoding a putative membrane of unknown function, that is essential for Streptococcus suis serotype 2 virulence.Veterinary research · 2026Article
- Article
- Designing a novel multiepitope vaccine candidate against Treponema pallidum via adhesins using reverse vaccinology.Scientific reports · 2026Article
- Evaluation of trained immunity as a potential strategy for a universal Streptococcus suis vaccine using immunogenic proteins in a murine model.BMC veterinary research · 2026Article
- From models to medicine: systematic development and evaluation of animal models forFrontiers in immunology · 2026Review
- Preparation of a multiepitope vaccine candidate for camel bocavirus and evaluation of its immunogenicity in a mouse model.Frontiers in immunology · 2026Article
- Identification and Evaluation of Conserved Subunit Vaccine Candidates Conferring Cross-Serotype Protection AgainstTransboundary and emerging diseases · 2026Article
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
- Recombinant Extracellular Factor Protein ofVaccines · 2025Article
- Article
- Adjuvant screening of an inactivated Pasteurella multocida vaccine in mice and evaluation of its immunogenicity in sheep.Veterinary research communications · 2025Article
- Development and Characterization of a Recombinant galT-galU Protein for Broad-Spectrum Immunoprotection Against Porcine Contagious Pleuropneumonia.International journal of molecular sciences · 2025Article
- Rational design of multi-epitope vaccine for Chandipura virus using an immunoinformatics approach.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Streptococcus suis infection represents a major challenge in pig farming and public health due to its zoonotic potential and diverse serotypes, while existing vaccines lack effective cross-protection. This study employed reverse vaccinology and immunoinformatics to identify 8 conserved proteins across 11 prevalent serotypes of S. suis. 16 candidate epitopes were selected to design three multi-epitope antigens against S. suis (designated as MEASs), which fused with a dendritic cell-targeting peptide to improve antigen presentation in host. Purified MEASs displayed favorable cross-reactogenicity against 29 serotype-specific antiserums. Robust humoral and cellular immune responses can be induced by MEAS 1 and MEAS 3 in a mouse model, which provided substantial protection against virulent strains from two different serotypes. In particular, their immune serums exhibited positive opsonization effects within bloodstream and macrophage phagocytosis. Taken together, we identified two promising MEASs with excellent cross-protection, offering potential in preventing S. suis infections in a mouse model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.